Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,311 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,642 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) | not yet recruiting | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07459543 | A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India | not yet recruiting | Phase 4 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760610 | Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response | not yet recruiting | Phase 4 | 27 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07281547 | Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain | not yet recruiting | Phase 4 | 20 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07664956 | Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | not yet recruiting | Phase 4 | 36 | Christiana Care Health ServicesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07462663 | SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer(SHAPE-ENDO) | not yet recruiting | Phase 4 | 80 | Hospital Universitari de BellvitgeOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07191379 | Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma(SCILLA) | not yet recruiting | Phase 4 | 50 | Odense University HospitalOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia(E-STOP2) | not yet recruiting | Phase 4 | 136 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07567313 | Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy | not yet recruiting | Phase 4 | 166 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT07546669 | Efficacy of Zoster Vaccination in Glioblastoma Patients(STARGATE) | not yet recruiting | Phase 4 | 230 | University Hospital, EssenOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07502027 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 4 | 55 | Huazhong University of Science and TechnologyOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07312370 | Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing | not yet recruiting | Phase 4 | 120 | LanZhou UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07474961 | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.(BLOOD-dose) | not yet recruiting | Phase 4 | 400 | Anne Louise Tølbøll SørensenOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens(AmiCARE) | not yet recruiting | Phase 4 | 122 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07358975 | Prediction of Complications in Hepatic Tumors | not yet recruiting | Phase 4 | 192 | Rigshospitalet, DenmarkOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07354698 | Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery(MHI) | not yet recruiting | Phase 4 | 114 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07334535 | Isa-VRD in TIE HRMM | not yet recruiting | Phase 4 | 117 | Peking Union Medical College HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07320534 | Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase | not yet recruiting | Phase 4 | 124 | Gadjah Mada UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial | not yet recruiting | Phase 4 | 30 | Zhengzhou UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07160361 | Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB | not yet recruiting | Phase 4 | 56 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07075250 | Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study(RIFOC003) | not yet recruiting | Phase 4 | 30 | Peking University People's HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 45 | Beijing GoBroad HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07004335 | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study | not yet recruiting | Phase 4 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06956092 | Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma(Glofitamab) | not yet recruiting | Phase 4 | 40 | Zhengzhou UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment(BRCSRRRHCCART) | not yet recruiting | Phase 4 | 704 | Zhiyun YangOTHER | 0 | Apr 11, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT05944783 | Bioequivalence Studies of Dasatinib 100 Mg(BE-Dasatinib) | not yet recruiting | Phase 4 | 46 | Centro de Atencion e Investigacion MedicaNETWORK | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06665737 | Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients(G-CSF in NHL) | not yet recruiting | Phase 4 | 126 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06785974 | Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis(SPIRAL) | not yet recruiting | Phase 4 | 140 | Erasmus Medical CenterOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06761911 | BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma | not yet recruiting | Phase 4 | 100 | Xiuhua SunOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06640738 | Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation | not yet recruiting | Phase 4 | 60 | Kaohsiung Medical UniversityOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06582186 | Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm(VORIPRECI) | not yet recruiting | Phase 4 | 30 | University Hospital, GrenobleOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06388135 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 4 | 80 | Yang Jianjun, PhDOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials